Advertisement
Canada markets close in 2 hours 47 minutes

  • S&P/TSX

    21,851.38
    -22.34 (-0.10%)
     

  • S&P 500

    5,034.60
    -37.03 (-0.73%)
     

  • DOW

    38,012.69
    -448.23 (-1.17%)
     

  • CAD/USD

    0.7311
    +0.0013 (+0.18%)
     

  • CRUDE OIL

    82.45
    -0.36 (-0.43%)
     

  • Bitcoin CAD

    88,579.56
    -100.28 (-0.11%)
     

  • CMC Crypto 200

    1,391.53
    +8.95 (+0.65%)
     

  • GOLD FUTURES

    2,340.20
    +1.80 (+0.08%)
     

  • RUSSELL 2000

    1,974.71
    -20.72 (-1.04%)
     

  • 10-Yr Bond

    4.6980
    +0.0460 (+0.99%)
     

  • NASDAQ

    15,551.06
    -161.68 (-1.03%)
     

  • VOLATILITY

    16.37
    +0.40 (+2.50%)
     

  • FTSE

    8,078.86
    +38.48 (+0.48%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • CAD/EUR

    0.6807
    -0.0012 (-0.18%)
     
MARKETS LIVE BLOG:

STOCKS SLIDE AFTER META'S REALITY CHECK, DOWNBEAT GDP

Caterpillar sinks 7% after earnings, management sees weakness in Europe, Asia-Pacific

NuGen Medical Devices begins feasibility study in the Netherlands for InsuJet and Ozempic

News Direct
·1 min read

Vancouver --News Direct-- NuGen Medical Devices

NuGen Medical Devices executive chairman Tony Di Benedetto joined Steve Darling from Proactive to provide details about the company that is developing the next generation of needle-free technologies for both humans and animals.

Di Benedetto shares with Proactive more about the technology behind products InsuJet and PetJet and also about an assessment and feasibility study in the Netherlands of InsuJet for Semaglutide or its more widely known name Ozempic.

Contact Details

Proactive Investors

+1 604-688-8158

na-editorial@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/nugen-medical-devices-begins-feasibility-study-in-the-netherlands-for-insujet-and-ozempic-884076141